著者

Kosaku Mimura Leo Yamada Daisuke Ujiie Suguru Hayase Takeshi Tada Hiroyuki Hanayama Aung Kyi Thar Min Masahiko Shibata Tomoyuki Momma Zenichiro Saze Shinji Ohki Koji Kono

出版者

THE FUKUSHIMA SOCIETY OF MEDICAL SCIENCE

雑誌

FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (ISSN:00162590)

巻号頁・発行日

pp.2018-09, (Released:2018-07-27)

参考文献数

48

被引用文献数

28

---

Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.